Exubera launch

Pfizer's launch of the inhaled insulin Exubera is slated for June, Human Health President Karen Katen said during an investor meeting Feb. 10. The company had previously said the timeline for launch was mid-year due to supply chain issues, the need for physician education and reimbursement discussions (1"The Pink Sheet" Feb. 13, 2006, p. 23). Katen noted that Pfizer has not yet announced Exubera's pricing but stated "we will possibly announce it" prior to the June lunch. Exubera was approved Jan. 27 for the treatment of adults with type 1 and type 2 diabetes...

Pfizer's launch of the inhaled insulin Exubera is slated for June, Human Health President Karen Katen said during an investor meeting Feb. 10. The company had previously said the timeline for launch was mid-year due to supply chain issues, the need for physician education and reimbursement discussions (¹ (Also see "Exubera Education, Complicated Manufacturing Impacting Launch Timeline" - Pink Sheet, 13 Feb, 2006.), p. 23). Katen noted that Pfizer has not yet announced Exubera's pricing but stated "we will possibly announce it" prior to the June lunch. Exubera was approved Jan. 27 for the treatment of adults with type 1 and type 2 diabetes....